- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Register
- Vet centr
- Meloxidyl
Pharmaceuticals - Community Register
Community register of veterinary medicinal products |
AUTHORISED |
Product information |
Invented name: | Meloxidyl
![]() |
Auth. number : | EU/2/06/070 |
Active substance : | Meloxicam |
ATC: | Anatomical main group: QM - Musculo-skeletal system Therapeutic subgroup: QM01 - Antiinflammatory and antirheumatic products Pharmacological subgroup: QM01A - Antiinflammatory and antirheumatic products, non-steroids Chemical subgroup: QM01AC - Oxicams Chemical substance: QM01AC06 - meloxicam (See WHO ATCvet Index) |
Indication: | Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery. Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats. Cattle: For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain following dehorning in calves. Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis–metritis–agalactia syndrome) with appropriate antibiotic therapy. Horses: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. For the relief of pain associated with equine colic. |
Marketing Authorisation Holder: | Ceva Santé Animale
10 avenue de la Ballastière, 33500 Libourne, France |
EPAR and active package presentations![]() | |
Package presentations |
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information". Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register. |
European Commission procedures |
Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
18/01/2007 | Centralised - Authorisation | EMEA/V/C/115 | (2007)165 of 15/01/2007 | |||
29/01/2007 | Centralised - Variation | EMEA/V/C/115/IB/1 | ||||
Updated with Decision(2007)4234 of 07/09/2007 | ||||||
11/09/2007 | Centralised - Variation | EMEA/V/C/115/IB/1 | (2007)4234 of 07/09/2007 | |||
12/10/2009 | Centralised - Variation | EMEA/V/C/115/X/2 | (2009)7849 of 08/10/2009 | |||
12/03/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/V/C/115/IA/5 | ||||
15/03/2010 | Centralised - Variation | EMEA/V/C/115/IA/6 | ||||
Updated with Decision(2010)6014 of 26/08/2010 | ||||||
30/03/2010 | Centralised - Variation | EMEA/V/C/115/X/3 | (2010)2171 of 26/03/2010 | |||
09/07/2010 | Centralised - Variation | EMEA/V/C/115/IB/7 | ||||
Updated with Decision(2011)563 of 27/01/2011 | ||||||
27/08/2010 | Centralised - Variation | EMEA/V/C/115/X/4 | (2010)6014 of 26/08/2010 | |||
27/10/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/V/C/115/IA/8 | ||||
01/02/2011 | Centralised - Variation | (2011)563 of 27/01/2011 | ||||
14/02/2011 | Centralised - Variation (no change in Commission Decision) | EMEA/V/C/115/IB/9 | ||||
21/12/2011 | Centralised - Variation | EMEA/V/C/115/IB/10 | ||||
Updated with Decision(2011)9943 of 19/12/2011 | ||||||
21/12/2011 | Centralised - Renewal | EMEA/V/C/115/R/11 | (2011)9943 of 19/12/2011 | |||
08/06/2012 | Centralised - Variation | EMEA/V/C/115/IB/12 | ||||
Updated with Decision(2012)7890 of 29/10/2012 | ||||||
31/10/2012 | Centralised - Variation | (2012)7890 of 29/10/2012 | ||||
21/12/2012 | Centralised - Variation | EMEA/V/C/115/IA/15 | ||||
Updated with Decision(2013)9712 of 18/12/2013 | ||||||
20/12/2013 | Centralised - Yearly update | (2013)9712 of 18/12/2013 | ||||
02/04/2014 | Centralised - 2-Monthly update | EMEA/V/C/115/IB/17 | (2014)2249 of 31/03/2014 | |||
01/10/2015 | Centralised - Variation | EMEA/V/C/115/IB/20/G | ||||
Updated with Decision(2016)6445 of 03/10/2016 | ||||||
05/10/2016 | Centralised - Yearly update | (2016)6445 of 03/10/2016 | ||||
18/01/2018 | Centralised - Variation | EMEA/V/C/115/II/23/G | ||||